Redmile Group has significantly increased its conviction in Nurix Therapeutics, adding 4.4 million shares valued at $63.43 million to its existing position. The investment brings the fund's total stake to 11.31% of assets under management, representing a substantial allocation to the biotech company despite a 6.5% decline in stock price over the past twelve months.
The fund's expansion of its Nurix position comes as the company's lead candidate, a BTK degrader, advances toward registrational trials. The program demonstrated clinical promise in Phase 1 testing, with data showing an 83% objective response rate—a metric that may have supported Redmile's decision to deepen its investment despite recent stock weakness.
The move underscores a key dynamic in biotech investing, where portfolio managers sometimes increase exposure during periods of underperformance when they view the decline as disconnected from fundamental developments. For Nurix shareholders, the substantial backing from a major institutional investor signals confidence in the clinical pathway ahead, though biotech investments carry inherent risks tied to regulatory outcomes and trial success rates.